Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvia miltiorrhiza paste plus fibroblast growth factor versus triamcinolone acetonide plus salvia miltiorrhiza injection for oral submucous fibrosis
ChiCTR2200065845Phase 4Not yet recruiting
- Sponsor
- Hunan Xiangya Stomatological Hospital of Central South University
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of salvia miltiorrhiza and triamcinolone in Oral submucous fibrosis (OSF) (2 arms), sponsored by Hunan Xiangya Stomatological Hospital of Central South University. Primary endpoints: Mouth opening, Burning sensation and 3 more. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
salvia miltiorrhizatriamcinolone
03
Conditions
Oral submucous fibrosis (OSF)
Beyond the preview
Go deeper on ChiCTR2200065845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065845.